Related Experiment Video
Updated: Feb 11, 2026
Model of Ischemia and Reperfusion Injury in Rabbits
Published on: November 3, 2023
Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury
Junaid Ansari1, Gaganpreet Kaur2, Felicity N E Gavins3,4
1Department of Molecular & Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA 71130, USA. jansar@lsuhsc.edu.
Insights
Annexin A1 (AnxA1) is a key mediator that reduces inflammation and thrombosis. This review explores AnxA1's protective role against ischemia-reperfusion injury (I/RI) in cardiovascular diseases.
Area of Science:
- Cardiovascular research
- Inflammation and thrombosis
- Vascular pathology
Background:
- Cardiovascular disease (CVD) is a leading global cause of death.
- Inflammation and thrombosis are key complications of CVD, leading to ischemic events.
- Reperfusion therapy for ischemic events can cause ischemia-reperfusion injury (I/RI).
Purpose of the Study:
- To review the protective role of Annexin A1 (AnxA1) in mitigating ischemia-reperfusion injury (I/RI).
- To explore the interaction between AnxA1 and formyl peptide receptors (FPR) in vascular pathologies.
Main Methods:
- Literature review of AnxA1's function in I/RI models.
- Analysis of AnxA1's anti-inflammatory and pro-resolving properties.
- Examination of AnxA1's interaction with the FPR family.
Main Results:
- AnxA1 acts as an endogenous anti-inflammatory and pro-resolving mediator.
- AnxA1 has demonstrated significant effects in resolving inflammation across various disease models.
- Evidence suggests AnxA1 mitigates I/RI complications by interacting with FPRs.
Conclusions:
- Annexin A1 plays a crucial protective role in managing ischemia-reperfusion injury (I/RI).
- AnxA1's anti-inflammatory and pro-resolving actions are vital for cardiovascular health.
- Targeting AnxA1 or its pathways may offer therapeutic strategies for I/RI.
Abstract:
Cardiovascular disease (CVD) continues to be the leading cause of death in the world. Increased inflammation and an enhanced thrombotic milieu represent two major complications of CVD, which can culminate into an ischemic event. Treatment for these life-threatening complications remains reperfusion and restoration of blood flow. However, reperfusion strategies may result in ischemia-reperfusion injury (I/RI) secondary to various cardiovascular pathologies, including myocardial infarction and stroke, by furthering the inflammatory and thrombotic responses and delivering inflammatory mediators to the affected tissue. Annexin A1 (AnxA1) and its mimetic peptides are endogenous anti-inflammatory and pro-resolving mediators, known to have significant effects in resolving inflammation in a variety of disease models. Mounting evidence suggests that AnxA1, which interacts with the formyl peptide receptor (FPR) family, may have a significant role in mitigating I/RI associated complications. In this review article, we focus on how AnxA1 plays a protective role in the I/R based vascular pathologies.
Related Concept Videos
01:13Therapeutic Index
00:52Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
03:02Standard Electrode Potentials
02:58Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
01:30Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
01:21The Resting Membrane Potential